AbbVie (ABBV) EPS (Basic) Growth (1y) (2013 - 2026)
AbbVie (ABBV) EPS (Basic) Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -92.05% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 65.24% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -636.10% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -69.49% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -90.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284.05% |
| Mar 31, 2026 | -45.99% |
| Dec 31, 2025 | 7,991.30% |
| Sep 30, 2025 | -87.98% |
| Jun 30, 2025 | -31.46% |
| Mar 31, 2025 | -6.00% |
| Dec 31, 2024 | -102.79% |
| Sep 30, 2024 | -12.28% |
| Jun 30, 2024 | -32.30% |
| Mar 31, 2024 | 1,515.23% |
| Dec 31, 2023 | -66.61% |
| Sep 30, 2023 | -54.83% |
| Jun 30, 2023 | 118.80% |
| Mar 31, 2023 | -102.16% |
| Dec 31, 2022 | -38.92% |
| Sep 30, 2022 | 24.21% |
| Jun 30, 2022 | 20.61% |
| Mar 31, 2022 | 26.24% |
| Dec 31, 2021 | 9,925.30% |
| Sep 30, 2021 | 37.41% |